Chloe Ramirez
Monkeypox is a rare disease with symptoms similar to but milder than smallpox. However, monkeypox can be fatal. Monkeypox is an emerging threat to humans since a new outbreak in May 2022. It is hypothesized that the cessation of the smallpox vaccination campaign in the 1980s is one of the leading causes of the current outbreak. Studies suggest that the smallpox vaccine is 80.7% efficacious in preventing monkeypox and that immunity from prior vaccination is long-lasting. The smallpox vaccine is also effective in reducing the risk of severe monkeypox infection. The CDC has recommended the JYNNEOS vaccine, a 2-dose vaccine developed to protect against smallpox and monkeypox, for individuals 18 years and older who are at high risk of infection.
| Characteristics | Values |
|---|---|
| Smallpox vaccine effectiveness against monkeypox | 80.7% or 85% |
| Smallpox vaccine immunity duration | Long-lasting |
| Monkeypox severity compared to smallpox | Less severe |
| Monkeypox symptoms | Fever, chills, headache, body aches, swollen lymph nodes, fatigue |
| Monkeypox mortality rate | Can cause death |
| Monkeypox outbreak regions | Africa, United States |
| Monkeypox outbreak year | 2022 |
| Smallpox vaccine types | JYNNEOS, ACAM2000 |
| JYNNEOS administration | 2 doses, 4 weeks apart |
| JYNNEOS suitability | Individuals 18 years and older, including immunocompromised |
| ACAM2000 administration | Single dose, percutaneous |
| ACAM2000 suitability | Individuals at high risk |
Explore related products
What You'll Learn
Smallpox vaccination may offer protection against monkeypox
Monkeypox and smallpox are related diseases, with monkeypox causing less severe symptoms than smallpox. Monkeypox is an emerging threat to humans since a new outbreak in May 2022. It is hypothesised that the increase in immunologically naive people after the cessation of the smallpox vaccination campaign in the 1980s is one of the leading causes of the outbreak.
Several studies have been conducted to evaluate the effectiveness of the smallpox vaccine in preventing monkeypox. A meta-analysis and systematic review of the literature found that the smallpox vaccine was 80.7% efficacious in preventing monkeypox and that the immunity provided was long-lasting. The review also showed that infection rates were lower in the smallpox-vaccinated group compared to the unvaccinated group. Another study reported that early smallpox vaccine immunization demonstrated a degree of protection against monkeypox, although the findings may not be broadly representative due to limited assessment indicators and study regions.
Currently, there are two FDA-approved vaccines for the prevention of smallpox and monkeypox (mpox): JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine that can be safely used in immunocompromised individuals and those at high risk for smallpox or mpox infection. ACAM2000 is a live, replicating vaccinia virus vaccine administered as a single dose and is also indicated for individuals at high risk.
In summary, while the precise degree of protection is not yet fully understood, smallpox vaccination appears to offer a significant level of protection against monkeypox. The available data and studies suggest that the smallpox vaccine is efficacious in preventing monkeypox infection and reducing the risk of severe disease.
FDA-Approved Vaccines: What You Need to Know
You may want to see also
Explore related products
Smallpox and monkeypox are related diseases
Smallpox vaccination has been found to be effective in preventing monkeypox. Studies have shown that the smallpox vaccine is at least 80-85% efficacious in preventing monkeypox infection, and the immunity provided is long-lasting. The protection data showed that smallpox vaccination effectively reduced the risk of severe monkeypox infection.
The smallpox vaccine is made using a weakened live vaccinia virus and cannot cause smallpox, monkeypox, or any other infectious disease. There are currently two FDA-approved vaccines for the prevention of smallpox and monkeypox (now referred to as mpox): JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine and can be safely used in significantly immunocompromised individuals. ACAM2000, on the other hand, is a live, replicating vaccinia virus vaccine administered as a single dose.
While the smallpox vaccine provides protection against monkeypox, it is important to note that the precise degree of protection is not yet known, especially for older adults who were vaccinated against smallpox many years ago. Researchers suggest that while these individuals may still be susceptible to monkeypox infection, they are likely to experience only mild symptoms.
Migrant Children: Are They Vaccinated Upon Arrival?
You may want to see also
Explore related products
Monkeypox is an emerging threat to humans
The World Health Organization (WHO) has acknowledged the ongoing monkeypox outbreak and is transitioning from using the term "monkeypox" to "mpox" to minimize any negative impact of the former name. The FDA has approved two vaccines for the prevention of mpox: JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine developed to protect against mpox and smallpox, while ACAM2000 is a single-dose vaccine.
The CDC has recommended that individuals with certain risk factors get vaccinated to protect themselves from mpox. Vaccination is a crucial tool in curbing the spread of mpox. The JYNNEOS vaccine can be safely administered to immunocompromised individuals, while ACAM2000 is intended for those at high risk of smallpox or mpox infection.
While the smallpox vaccine provides some protection, it is not a perfect solution. The precise degree of protection is still unknown, and the vaccine may not be easily accessible to everyone. Additionally, the cessation of the smallpox vaccination campaign in the 1980s has left a significant portion of the population immunologically naive, increasing their vulnerability to monkeypox.
To summarize, monkeypox poses a growing danger to human health, and the smallpox vaccine offers a degree of protection against it. However, the ongoing outbreak underscores the importance of vaccination and public health measures to prevent the spread of mpox and safeguard vulnerable populations.
Vaccines for Employees: Which BBP Has Them?
You may want to see also
Explore related products
Smallpox vaccine may reduce the risk of severe monkeypox
Monkeypox is a rare disease with symptoms similar to but milder than smallpox. However, monkeypox can be fatal. Monkeypox is an emerging infection in Africa, and outbreaks of imported cases sometimes occur in other countries, including the United States. Monkeypox is related to smallpox, but it is less severe, and for most infected people, the symptoms resemble those of the flu. Monkeypox is an emerging threat to humans since a new outbreak in May 2022. It is hypothesized that the increasing immunologically naive population after the cessation of the smallpox vaccination campaign in the 1980s is one of the leading causes of the outbreak.
Smallpox vaccination is essential for preventing further smallpox outbreaks. Several studies have evaluated the effectiveness, protection, safety, and cross-immunogenicity of smallpox vaccines in preventing monkeypox infection. The Centers for Disease Control and Prevention (CDC) states that, based on past data collected in Africa, the smallpox vaccine is at least 85% effective in preventing monkeypox. However, since this is a new situation, the precise degree of protection is unknown. The CDC also mentions that older adults who have been vaccinated against smallpox may still be susceptible to monkeypox infection but are likely to experience only mild symptoms.
A comprehensive meta-analysis and systematic review of the literature found that the smallpox vaccine was 80.7% efficacious in preventing human monkeypox, and the immunity provided was long-lasting. The protection data showed that smallpox vaccination effectively reduced the risk of severe monkeypox infection. The infection rates were significantly lower in the smallpox-vaccinated group compared to the unvaccinated group.
There are currently two FDA-approved vaccines for the prevention of smallpox and monkeypox (mpox): JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine developed to protect against mpox and smallpox and can be safely used in immunocompromised individuals. ACAM2000 is a live, replicating vaccinia virus vaccine administered as a single dose. It is important to note that the findings related to the smallpox vaccine's effectiveness against monkeypox may not be broadly representative due to limitations in assessment indicators and study regions.
Hepatitis B Vaccine: Who Pays for Protection?
You may want to see also
Explore related products
The smallpox vaccine is long-lasting
The smallpox vaccine has been a topic of interest since the recent outbreak of monkeypox in 2022. Monkeypox is a rare disease with symptoms similar but milder than smallpox. However, it can be fatal. Monkeypox is related to smallpox, but the disease it causes is less severe.
The smallpox vaccine is believed to offer protection against monkeypox. The Centers for Disease Control and Prevention (CDC) states that the smallpox vaccine is at least 85% effective in preventing monkeypox. Past studies have shown that people who were previously vaccinated against smallpox have higher immunity and experience fewer adverse events after vaccination than those receiving the vaccine for the first time.
The smallpox vaccine's protection against monkeypox has been supported by various studies. One study reported that early smallpox vaccine immunization demonstrated a degree of protection against monkeypox. Another comprehensive meta-analysis evaluated the effectiveness, protection, safety, and cross-immunogenicity of the smallpox vaccine in preventing monkeypox infection. The results showed that infection rates were significantly lower in the vaccinated group, and the vaccine effectively reduced the risk of severe infection.
Additionally, the smallpox vaccine's immunity is long-lasting. A systematic review of relevant articles suggested that smallpox vaccination is 80.7% efficacious in preventing monkeypox, and the immunity provided is long-lasting. This is further supported by the fact that older adults who received the smallpox vaccine decades ago may still have some level of protection against monkeypox, even if they are susceptible to infection, they are likely to experience only mild symptoms.
The FDA has approved two vaccines for the prevention of smallpox and monkeypox: JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine and can be safely used in immunocompromised individuals. ACAM2000 is a single-dose vaccine administered percutaneously by puncturing the skin of the upper arm multiple times.
Traveling to the US? Vaccination Requirements You Need to Know
You may want to see also
Frequently asked questions
Studies suggest that the smallpox vaccine is 80.7% efficacious in preventing monkeypox. The smallpox vaccine provides long-lasting immunity against monkeypox.
Monkeypox symptoms are similar to the flu and include fever, chills, headache, body aches, swollen lymph nodes, and fatigue. Monkeypox can cause death, but the disease it causes is not as severe as smallpox.
The FDA has approved two vaccines for the prevention of monkeypox: JYNNEOS and ACAM2000. JYNNEOS is a 2-dose vaccine and can be administered to individuals 18 years and older. ACAM2000 is a single-dose vaccine.
The second dose of the JYNNEOS vaccine should be administered 4 weeks (28 days) after the first dose. While the first dose provides some protection, two doses are recommended for stronger protection.
